Accelerated Cure Project Welcomes New Chief Scientific Officer
"In my various roles as a patient, advocate, clinician, and researcher, I strive to better understand the molecular drivers of disease, deliver personalized care, and educate diverse stakeholders with the goal of bettering the lives of people living with MS,"
In addition to clinical work,
"ACP and iConquerMS have established a premier program in patient-powered research and are making significant contributions to the field and to improving the lives of people with MS. I am very pleased to be leaving the program in such capable hands and look forward to seeing the new paths forged under Stephanie's leadership," says
Founded in 2001, ACP is a non-profit organization dedicated to speeding research efforts to improve diagnosis, optimize treatments, and eventually cure MS, guided first and foremost by the needs and priorities of those affected by the disease. ACP partners with researchers around the world and provides them with access to the biospecimens, data, and people they need to conduct their work. ACP's research resources include the ACP Repository, a collection of highly characterized biosamples and data from more than 3,200 subjects, as well as iConquerMS, a network of more than 8,500 people affected by MS who share information, insights, and lived experience to accelerate research and innovation. In addition, ACP convenes the MS Minority Research Engagement Partnership Network and the Research Inclusion, Diversity, and Equity Council, which provide insights into motivators and barriers to participation in research for those from historically underrepresented populations.
"Stephanie's appointment is a rare opportunity to bring together research, clinical and lived experience in MS," says
CONTACT
Melissa Glim
Ogilvy Health
About Accelerated Cure Project
ACP (www.acceleratedcure.org) is a patient-founded non-profit organization dedicated to accelerating research efforts to improve the health, healthcare and quality of life of people affected by MS. The organization promotes scientific collaboration and accelerates research by rapidly and cost-effectively providing researchers worldwide with people, data and biosample resources they need to explore novel research ideas that can lead to cures and better care for people living with MS. The major programs of Accelerated Cure Project are the ACP Repository, the iConquerMS™ People-Powered Research Network and the MS Minority Research Engagement Partnership Network.
About the iConquerMS People-Powered Research Network
iConquerMS™ (www.iConquerMS.org) is a research initiative by and for individuals living with MS who contribute their ideas and their health data. iConquerMS™ was established in 2014 by the Accelerated Cure Project for MS, in partnership with Feinstein Kean Healthcare and Arizona State University. Initial funding for iConquerMS™ was provided by the Patient-Centered Outcomes Research Institute (PCORI) (www.PCORI.org). Over 8,000 individuals living with MS are currently registered as iConquerMS™ research participants, constituting a large and growing cohort for data-driven research into topics that matter most to people affected by MS. iConquerMS™ achieves its purpose, to improve the health, healthcare and quality of life of people affected by MS, through collaborations with
View original content to download multimedia:https://www.prnewswire.com/news-releases/accelerated-cure-project-welcomes-new-chief-scientific-officer-302210023.html
SOURCE Accelerated Cure Project for Multiple Sclerosis
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DELLA Celebrates 14th Anniversary with Annual DELLA Day and Announces New Build Your Own System Experience
- Understanding Lymph System Supplements: Nation Health MD Highlights Natural Support for Everyday Lymphatic Wellness
- Speediance Showcases the Future of Intelligent Home Fitness at HomeGymCon 2026
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share